Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VERI-101
- Development stage
- Preclinical
- Lead developer
- VerImmune
- Modality
- Vaccines & Immunotherapeutics
01
Overview
VERI-101 is a first-in-class investigational cancer immunotherapy developed by VerImmune that uses a proprietary Virus-inspired Particle (ViP) platform to implement an Anti-tumor Immune Redirection (AIR) strategy, redirecting pre-existing cellular immune memory against cytomegalovirus (CMV) toward tumor cells to induce antitumor CD8+ T-cell responses.[1][5][7][14] As an AIR-ViP “Virus-inspired Drug Conjugate,” VERI-101 is designed to be tumor antigen-agnostic and to function as an immunostimulatory agent that can be used alone or in combination with immune checkpoint inhibitors for multiple solid tumors, with development currently in the preclinical stage and partnered with Fosun Pharma for clinical development and commercialization in Greater China.[1][2][4][7][12][13][14]
- Other names
- Anti-tumor Immune Redirection Virus-inspired Particle VERI-101AIR-ViP VERI-101
Beyond the preview
Go deeper on VERI-101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VERI-101.